Effect of pyrazinoyl guanide on lipid &carbohydrate metabolism in NIDDM
$0M01FY2001RRNIH
Temple University, Philadelphia PA
Investigators
Linked publications & trials
Paper 30137555Paper 20194829Paper 17949927Paper 17120297Paper 17071216Paper 16961692Paper 16868831Paper 16768601Paper 16720337Paper 16457777Paper 16416175Paper 16272292Paper 15932362Paper 15916622Paper 15800559Paper 15767618Paper 15235061Paper 15107299Paper 15104362Paper 15086868Paper 15056089Paper 14720034Paper 14717972Paper 14624413Paper 12962693Paper 12866995Paper 12832307Paper 12757160Paper 12660140Paper 12546685Paper 12141833Paper 12135014Paper 12034027Paper 12028371Paper 11768254Paper 11743243Paper 11323422Paper 11270790Paper 11270782Paper 11181007Paper 11051357Paper 11007121Paper 10898747Paper 10644487
Abstract
This is a pilot study involving 2 patients in which a drug - Pyrazinoyl will be studied to assess its effect on lipid and carbohydrate metabolism. This agent has been shown in humans (and rats) to decrease blood glucose in patients with diabetes, and the mechanism is thought to be via its ability to lower plasma FFA and triglyceride concentration. The lipid lowering effect is believed to result from its inhibition of lipolysis secondary to activation of adipose tissue phosphodiesterase activity and a decrease in cAMP.
View original record on NIH RePORTER →